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esponsibility of InsAbstract Salvianolic acids, including salvianolic acid A (SAA) and salvianolic acid B (SAB), are
the main water-soluble bioactive compounds isolated from the Chinese medicinal herb Danshen
and have been shown to exert in vitro and in vivo cardiovascular protection. Recent studies suggest
that epoxyeicosatrienoic acids (EETs), the primary cytochrome P450 2J (CYP2J) epoxygenase
metabolites of arachidonic acid, are involved in the progression of ischemic injury in diverse
organs. Here, we investigated the relation between the protective effects of salvianolic acids and
EETs/sEH as well as MAPK signaling pathway. In the present study, the rat acute myocardial
infarction (AMI) model was established by the left anterior descending coronary artery occlusion.
Our results showed that salvianolic acids signiﬁcantly reduced ST-segment elevation and serum
levels of CK-MB, LDH, and ALT in AMI rats, and signiﬁcantly attenuated the caspase 3
expression and reduced the ratio of Bax/Bcl-2. ELISA measurement showed that salvianolic acids
signiﬁcantly increased the 14,15-EET levels in blood and heart, and attenuated hydrolase activity of
sEH in heart of AMI rat. Western blotting analysis suggested that salvianolic acids signiﬁcantly
attenuated the phosphorylation of JNK and p38, and increased phosphorylation of ERK in heart.
In conclusion, these results indicate that EETs/sEH and MAPK signaling pathways are important
processes in cardioprotection of salvianolic acids.
& 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.edica, Chinese Academy of Medi
rved.
.006
63165184.
Guanhua Du).
titute of Materia Medica, Chinese Acal Sciences and Chinese Pharmaceutical Association. Production and
cademy of Medical Sciences and Chinese Pharmaceutical Association.
Shoubao Wang et al.261. Introduction
Danshen, the dried root of Salvia miltiorrhiza, is used in Chinese
medicine to treat vascular disease. According to Chinese medi-
cine theory, Danshen promotes blood ﬂow and resolves blood
stasis. Therefore, it is wildly prescribed to patients with angina
pectoris, acute myocardial infarction (AMI), hyperlipidemia, and
stroke. Recent studies show that there are more than 18
components in Danshen. They can be classiﬁed as water-
soluble (hydrophilic) phenolic compounds and nonpolar (lipid-
soluble) diterpenoidal compounds. Salvianolic acids are the main
water-soluble compounds in Danshen. Among salvianolic acids,
salvianolic acid A (SAA) and salvianolic acid B (SAB) are the
most abundant components. The structures of salvianolic acids
are shown in Fig. 1. Although the therapeutic potential of
salvianolic acids on hepatic protection1,2, neural protection3,4,
and cancer treatment5–7 have been proposed in recent years, the
greatest clinical impact of salvianolic acids is cardiovascular
protection.
In the past few years, mechanisms of how salvianolic acids
exert the cardiovascular protective effects have been investi-
gated. Many studies on endothelial cells, vascular smooth
muscle cells and cardiomyocytes suggest salvianolic acids may
exert cardiovascular protection via the multiple mechanisms in
terms of reactive oxygen species (ROS) scavenging ability,
leukocyte–endothelial adhesion regulation, inﬂammation inhi-
bition and immune-modulation8.
Epoxyeicosatrienoic acids (EETs), the primary cytochrome
P450 2J (CYP2J) epoxygenase metabolites of arachidonic acid,
possess potent and diverse biological effects within the
vasculature, i.e., vasodilatory, anti-inﬂammatory, anti-apop-
totic, and mitogenic effects9,10. Recent studies suggest that
active EETs are involved in the progression of ischemic injury
in diverse organs. Some studies show that the anti-apoptotic
effects of EETs were signiﬁcantly attenuated by inhibition of
MAPK signaling pathway11,12. It indicates that MAPK
signaling pathway plays an important role in beneﬁcialFigure 1 Chemical structures of salvianolic acid A (SAA) and
salvianolic acid B (SAB).biological effects of EETs. Soluble epoxide hydrolase (sEH)
is considered as the primary enzyme responsible for degrada-
tion of EETs to dihydroxyeicosatrienoic acids (DHETs) which
are less potent. Many studies indicate pharmacological inhibi-
tion of sEH protects rats against ischemic damage9,13,14.
Based on the perceived beneﬁcial effects of EETs, there was
little information about the relation between cardioprotection
of salvianolic acids and EETs/sEH. Here, we investigate the
protective effects of salvianolic acids involving EETs/sEH and
explore the role of MAPK signaling pathway using the rat
acute myocardial infarction model.2. Materials and methods
2.1. Chemicals and reagents
SAA and SAB (purity499%) were supplied by the Department
of Phytochemistry, Institute of Materia Medica (Beijing, China).
When used, they were freshly prepared in physiological saline to
reach appropriate concentrations. Antibodies of p38, phospho-
p38 and b-actin were obtained from Santa Cruz Biotechnology,
Inc. (CA, USA). Antibodies of caspase 3, MAPK/JNK, phos-
pho-MAPK/JNK, ERK, and phospho-ERK were obtained
from Cell Signaling Technology, Inc. (MA, USA). All other
chemicals and reagents were of analytical grade.2.2. Animals
Male Sprague-Dawley rats (220–250 g) were provided by Vital
River Laboratory Animal Center (Beijing, China). The pro-
tocol was approved by the institutional animal care and use
committee and the local experimental ethics committee. All
rats were kept on a 12-h light/12-h dark regime, with free
access to food and water. Room temperature (2572 1C) and
humidity (55710%) were controlled.2.3. Experimental procedure and treatment
AMI was induced by permanent ligation of the left anterior
descending coronary artery in rats, as described previously15.
Brieﬂy, rats were anaesthetized with urethane (1.0 g/kg, ip)
and ventilated with a volume-regulated respirator. After left
thoracotomy, the heart was exposed, and the left anterior
descending coronary artery was ligated approximately 2 mm
from its origin between the pulmonary artery conus and the
left atrium with a 5-0 prolene suture. The successful coronary
occlusion was veriﬁed by typical changes in Lead II ECG. Five
minutes after ligation, the rats were randomly divided into ﬁve
groups of 10 animals each: sham group, AMI group, 20 mg/kg
SAB group (SAB 20), 1 and 3 mg/kg SAA groups (SAA 1 and
SAA 3). All drugs were administered via tail vein injection
5 min after coronary occlusion. Sham group received the same
volume of saline.2.4. Electrocardiogram measurements
A bipolar lead with electrodes was placed on the right arm and
left leg. Lead II ECG monitoring was undertaken throughout
the experimental duration, and ST-segment (J point) elevation
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was considered.
2.5. Measurements of cardiac marker enzyme activity
After 6 h of coronary ligation, the rats were re-anaesthetized and
3 mL blood was drawn from the abdominal aorta. After
centrifuging at 1000 g, the serum was collected. The activities
of serum creatine kinase-MB (CK-MB), lactate dehydrogenase
(LDH) and alanine aminotransferase (ALT) were determined
spectrophotometrically using diagnostic kits according to the
manufacturer’s instructions (Jiancheng, Nanjing, China).
2.6. Measurement of 14,15-EET by ELISA
The 14,15-EET levels in the blood and heart were measured
with a commercial ELISA kit. Brieﬂy, blood or heart homo-
genate was collected in TPP (triphenylphosphine) with a ﬁnal
concentration of 0.1 mM. After acidiﬁcation with acetic acid
to a pH of approximately 3.0–4.0, the samples are extracted
three times with ethyl acetate. The collected organic phases
(ethyl acetate) were pooled and evaporated under nitrogen.
The above dried up residue was dissolved in 20 mL of ethanol,
and then 20 mL of acetic acid was added to make the pH
approximately 3.0–4.0, reacting for 12 h at 45 1C. In the acidic
conditions, EET is hydrolyzed to DHET. After the reaction,
add 1.5 volumes of water to the sample and extract three times
with equal volume of ethyl acetate. After three times of
extraction, all the organic phase (ethyl acetate) was pooled
together and evaporated under nitrogen. The sediment was
dissolved in 20 mL of ethanol for ELISA assay of 14,15-DHET
according to the manufacturer’s instructions. At the same
time, measure the 14,15-DHET level without hydrolysis of
14,15-EET in the same sample.
2.7. Assay for hydrolase activity of sEH
Hydrolase activity of sEH in heart was measured by incubat-
ing with 14,15-EET and assaying for 14,15-DHET. Brieﬂy,
heart was homogenized in 4 volumes of ice-cold buffer
(20 mM Tris–HCl, 0.32 M sucrose, 1 mM EDTA), centrifuged
at 1000 g for 10 min, and supernatant was further centri-
fuged at 10,000 g for 20 min. Hydrolase enzymatic reactions
were initiated by adding 1 mM 14,15-EET16 and incubated in
shaking water bath at 37 1C for 1 h. Then the 14,15-DHET
level was measured by ELISA according to the manufacturer’s
instructions.
2.8. Western blotting
Heart was homogenized for 30 min at 4 1C in 4 volumes of
RIPA lysis buffer (50 mM Tris–HCl, 150 mM NaCl, 1 mM
EDTA, 1% Triton x-100, 1% sodium deoxycholate, 0.1%
SDS, and 1 mM PMSF). After centrifuging at 12,000 g at
4 1C for 30 min and the protein concentration of the super-
natant was quantiﬁed using BioRad Dc Protein Assay kit.
Equal amounts of protein samples (n¼3 in each group) were
separated by SDS-PAGE and transferred to PVDF mem-
branes. After being blocked with Tris buffered saline, 0.1%
Tween 20 with 5% (w/v) non-fat milk, membranes loaded with
protein of interest were incubated with primary antibodies at4 1C overnight. HRP-conjugated secondary antibody (goat
anti-rabbit, 1:1000 dilution, Rockland, PA, USA) was used to
identify primary antibodies. Blots were developed with Super-
SignalWest Pico Chemiluminescent Substrate (Pierce, IL,
USA) and visualized using a ChemiDoc XRS system (BioRad,
PA, USA). The intensity of immunoreactive bands was
quantiﬁed using Quantity One Software (BioRad, PA, USA).
2.9. Statistical analysis
Data are presented as mean7SD. Statistical signiﬁcance was
determined by one-way analysis of variance (ANOVA) fol-
lowed by Dunnett’s test. All calculations were performed with
SPSS version 13.0 (SPSS Inc., IL, USA). Differences were
considered signiﬁcant if Po0.05.3. Results
3.1. Effects of salvianolic acids on electrocardiographic
parameters and levels of CK-MB, ALT and LDH
Fig. 2A demonstrated that the rats in AMI group showed a
marked elevation in ST-segments comparing to rats in
sham group. Treatment with SAB (20 mg/kg) and SAA (1 and
3 mg/kg, respectively) signiﬁcantly attenuated the elevation in
ST-segments at 240 min post infarction compared with the
AMI group (Po0.05 and Po0.01).
Fig. 2B–D showed that AMI induced increase in serum
cardiac marker enzyme activity in the rats. Treatment with
SAB (20 mg/kg) and SAA (1 and 3 mg/kg, respectively)
signiﬁcantly attenuated the increase in CK-MB, LDH and
ALT compared with the AMI group (Po0.01).
3.2. Effects of salvianolic acids on expression of caspase 3,
Bcl-2 and Bax in myocardial tissues
AMI resulted in a signiﬁcant reduction in Bcl-2 expression and
a signiﬁcant increase in Bax and caspase 3 expression.
Treatment with SAB (20 mg/kg) and SAA (1 and 3 mg/kg,
respectively) signiﬁcantly attenuated the caspase 3 expression
and reduced the ratio of Bax/Bcl-2 (Po0.05 and Po0.01)
(Fig. 3).
3.3. Effects of salvianolic acids on the level of 14,15-EET in
blood and heart
As shown in Fig. 4A and B, the 14,15-EET levels in blood and
heart in AMI rats were not different compared to sham rats.
Treatment with SAB (20 mg/kg) and SAA (1 and 3 mg/kg,
respectively) signiﬁcantly increased the 14,15-EET levels in
blood and heart (Po0.05 and Po0.01).
3.4. Effects of salvianolic acids on sEH activity in heart
As shown in Fig. 4C, there was no signiﬁcant difference in
heart sEH activity between sham and AMI rats as indicated by
the corresponding 14,15-DHET content. Treatment with SAB
(20 mg/kg) and SAA (1 and 3 mg/kg, respectively) signiﬁcantly
attenuated the sEH activity in heart (Po0.01).
Figure 3 Salvianolic acids altered levels of caspase-3, Bcl-2 and Bax after AMI. (A) Representative immunoblotting (upper) of caspase-3
and b-actin at 1:500 dilution of antibodies and densitometric analysis (bottom). (B) Representative immunoblotting (upper) of Bcl-2 and
Bax at 1:500 dilution of antibodies and densitometric analysis (bottom). Data are presented as mean7SD. The experiments were repeated
for 3 times. Po0.01 vs. sham group; ]Po0.05, ]]Po0.01 vs. AMI group.
Figure 2 Salvianolic acids reduced ST-segment elevation and levels of CK-MB, ALT and LDH in serum after AMI. (A) ST-segment
elevation in lead II ECG was calculated at the time point of 30 min after AMI. (B), (C) and (D) Levels of CK-MB, ALT and LDH in
serum were assayed using commercial diagnostic kits. Data are presented as mean7SD (n¼10). Po0.01 vs. sham group; ]Po0.05,
]]Po0.01 vs. AMI group.
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Figure 4 Salvianolic acids increased the 14,15-EET levels in blood and heart and attenuated heart sEH activity in AMI rats. (A) and (B)
The 14,15-EET levels in blood and heart. (C) The activity of sEH in heart as indicated by the corresponding 14,15-DHET content. Data
are presented as mean7SD (n¼10). ]Po0.05, ]]Po0.01 vs. AMI group.
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As shown in Fig. 5, there were signiﬁcant differences in
phosphorylation level of MAPK signaling pathway between
sham and AMI rats, as indicated by the ratio of phospho-/
total protein. Treatment with SAB (20 mg/kg) and SAA
(1 and 3 mg/kg, respectively) signiﬁcantly attenuated the
phosphorylation of JNK and p38, and increased phosphoryla-
tion of ERK in heart (Po0.01).4. Discussion
Salvianolic acids, which contain polyphenolic structure, are potent
antioxidants. Salvianolic acids reduce intracellular and intravas-
cular oxidative stress, which protects endothelial cells, arterial
smooth muscle cells, cardiomyocyte, and LDL from free radical
damage and peroxidation. ROS scavenging ability has been
regarded as the major mechanism of cardiovascular protection.
Recent researches focus on elucidating the other potential
pathways.
In the present study, we tested the hypothesis that EETs/sEH
and MAPK signaling pathways would play a vital role in
cardioprotection of salvianolic acids. Our results showed that
SAA and SAB, two representative ingredients of salvianolic
acids, provided potent protective effects on the rats with acutemyocardial infarction, as indicated by a signiﬁcant reduction in
ST-segment elevation and serum levels of cardiac ischemic
markers such as CK-MB, LDH and ALT after permanent
LAD occlusion. Acute myocardial infarction resulted in signiﬁ-
cant apoptosis of cardiacmyocyte. This process characterizes
with reduction in Bcl-2 expression and increase in Bax and
caspase 3 expression. Salvianolic acids signiﬁcantly attenuated
the caspase 3 expression and reduced the ratio of Bax/Bcl-2.
Like many eicosanoids, EETs have multiple biological
functions, including reduction of blood pressure, inﬂamma-
tion, ischemic injury and atherosclerosis in multiple species.
In vitro and in vivo studies verify that exogenous EETs have
potent protective effects on myocardial infarction17–19. Our
results showed that AMI did not signiﬁcantly alter the 14,15-
DHET and 14,15-EET levels in blood and heart compared to
sham rats, similar to previous ﬁndings. Maybe it is attributed
to the reason that AMI did not directly affect heart sEH
activity and there are other pathways than sEH pathway in the
metabolism of EETs. The results demonstrated that salviano-
lic acids signiﬁcantly increased the 14,15-EET levels in blood
and heart of rat subjected to AMI. EETs are regulated
through conversion to less active corresponding diols by
sEH. Inhibition of the sEH stabilizes EETs, thus, enhancing
the beneﬁcial effects of EETs. Our previous study showed that
SAA could inhibit recombinant human sEH activity in a
concentration-dependent manner (IC50¼1.62 mM) using a
Figure 5 Effects of salvianolic acids on MAPK signaling pathway. (A) Representative immunoblotting of p-JNK, JNK, p-p38, p38, p-
ERK and ERK at 1:1000 dilution of antibodies. The experiments were repeated for 3 times. (B), (C) and (D) Densitometric analysis of
immunoblotting bands in terms of p-JNK/JNK, p-p38/p38, and p-ERK/ERK. Data are presented as mean7SD. Po0.01 vs. sham
group; ]Po0.05, ]]Po0.01 vs. AMI group.
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showed that salvianolic acids signiﬁcantly attenuated heart
sEH activity of AMI rats as indicated by the corresponding
14,15-DHET content.
MAPKs play an important role in myocardial ischemia/
reperfusion injury19. Recent studies suggest that the beneﬁcial
biological effects of EETs require MAPK signaling pathway.
Our results showed that salvianolic acids signiﬁcantly attenu-
ated the phosphorylation of JNK and p38, and increased
phosphorylation of ERK in heart. These effects may be
derived from the direct action of salvianolic acids, also being
considered as the sequence of increasing EETs induced by
salvianolic acids. It will be conﬁrmed in further studies.
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